1
|
Collery P, Michalke B, Lucio M, Varlet D, Guigonis JM, Scimeca JC, Schmid-Antomarchi H, Schmid-Alliana A. Plasma Rhenium and Selenium Concentrations After Repeated Daily Oral Administration of Rhenium(I)-diselenoether in 4T1 Breast Tumor-bearing Mice. Anticancer Res 2023; 43:1017-1023. [PMID: 36854529 DOI: 10.21873/anticanres.16246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 09/02/2022] [Accepted: 09/06/2022] [Indexed: 03/02/2023]
Abstract
BACKGROUND/AIM Rhenium(I)-diselenoether (Re-diSe) is a compound combining a rhenium tricarbonyl(I) core with a diselenide ligand. A high dose of 60 mg/kg had a pro-tumor effect in a previous study, in non-immune deficient 4T1 tumor-bearing mice, while doses of 1 and 10 mg/kg did not affect tumor growth, after repeated oral administrations. This study aimed to examine the tumor effects of a lower dose of 0.1 mg/kg with the same experimental design and to assay plasma Re and Se concentrations. MATERIALS AND METHODS Syngenic BALB/cByJ (JAX) mice were orthotopically inoculated with 4T1 mammary breast cancer cells. Re-diSe was daily administered orally for 23 days at doses of 0.1, 1, and 10 mg/kg, whereas controls received no treatment. Tumor and mice weights were measured at the end of the experiment. Plasma Re and Se concentrations were assayed by an inductively coupled plasma sector field mass spectrometry instrument (ICP-sf-MS). RESULTS The weight of the tumors did not vary in treated versus non-treated mice. The limit of detection (LOD) of Re was 0.34 nmol/l. Plasma Re concentrations were 14±20 nmol/l at doses of 0.1 mg/kg, and increased at higher doses, up to 792±167 nmol/l at doses of 10 mg/kg. Plasma Se concentrations were significantly increased in mice treated with the dose of 0.1 mg/kg (4,262±1,511 nmol/l) versus controls (1,262±888 nmol/l), but not from 0.1 to 1 mg/kg, nor from 1 to 10 mg/kg. CONCLUSION The 0.1 mg/kg dose of Re-diSe resulted in detectable plasma Re concentrations and significantly increased plasma Se concentrations. In the future, doses as low as 0.1 mg/kg of Re-diSe will be tested, exploring its potential immune interest as a metronomic schedule of treatment, but in mouse models that readily develop extensive metastatic disease.
Collapse
Affiliation(s)
- Philippe Collery
- Société de Coordination de Recherches Thérapeutiques, Algajola, France;
| | - Bernhard Michalke
- Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Marianna Lucio
- Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | | | - Jean-Marie Guigonis
- Université Côte d'Azur, Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Fréderic Joliot, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Nice, France
| | | | | | | |
Collapse
|
2
|
Collery P, Lagadec P, Krossa I, Cohen C, Antomarchi J, Varlet D, Lucio M, Guigonis JM, Scimeca JC, Schmid-Antomarchi H, Schmid-Alliana A. Relationship between the oxidative status and the tumor growth in transplanted triple-negative 4T1 breast tumor mice after oral administration of rhenium(I)-diselenoether. J Trace Elem Med Biol 2022; 71:126931. [PMID: 35063816 DOI: 10.1016/j.jtemb.2022.126931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 01/12/2022] [Accepted: 01/14/2022] [Indexed: 10/19/2022]
Abstract
BACKGROUND Selective inhibitory effects of rhenium(I)-diselenoether (Re-diSe) were observed in cultured breast malignant cells. They were attributed to a decrease in Reactive Oxygen Species (ROS) production. A concomitant decrease in the production of Transforming Growth Factor-beta (TGFβ1), Insulin Growth Factor 1 (IGF1), and Vascular Endothelial Growth Factor A (VEGFA) by the malignant cells was also observed. AIM The study aimed to investigate the anti-tumor effects of Re-diSe on mice bearing 4T1 breast tumors, an experimental model of triple-negative breast cancer, and correlate them with several biomarkers. MATERIAL AND METHODS 4T1 mammary breast cancer cells were orthotopically inoculated into syngenic BALB/c Jack mice. Different doses of Re-diSe (1, 10, and 60 mg/kg) were administered orally for 23 consecutive days to assess the efficacy and toxicity. The oxidative status was evaluated by assaying Advanced Oxidative Protein Products (AOPP), and by the dinitrophenylhydrazone (DNPH) test in plasma of healthy mice, non-treated tumor-bearing mice (controls), treated tumor-bearing mice, and tumors in all tumor-bearing mice. Tumor necrosis factor (TNFα), VEGFA, VEGFB, TGFβ1, Interferon, and selenoprotein P (selenoP) were selected as biomarkers. RESULTS Doses of 1 and 10 mg/kg did not affect the tumor weights. There was a significant increase in the tumor weights in mice treated with the maximum dose of 60 mg/kg, concomitantly with a significant decrease in AOPP, TNFα, and TGFβ1 in the tumors. SelenoP concentrations increased in the plasma but not in the tumors. CONCLUSION We did not confirm the anti-tumor activity of the Re-diSe compound in this experiment. However, the transplantation of the tumor cells did not induce an expected pro-oxidative status without any increase of the oxidative biomarkers in the plasma of controls compared to healthy mice. This condition could be essential to evaluate the effect of an antioxidant drug. The choice of the experimental model will be primordial to assess the effects of the Re-diSe compound in further studies.
Collapse
Affiliation(s)
- Philippe Collery
- Société de Coordination de Recherches Thérapeutiques, 20220, Algajola, France.
| | - Patricia Lagadec
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Imène Krossa
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Charlotte Cohen
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Julie Antomarchi
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | | | - Marianna Lucio
- Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt, 85764, Neuherberg, Germany
| | - Jean-Marie Guigonis
- Université Nice Sophia Antipolis, Plateforme "Bernard Rossi", UFR de médecine Pasteur, UMR 4320, CEA TIRO, 06107, Nice cedex 2, France
| | - Jean-Claude Scimeca
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Heidy Schmid-Antomarchi
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| | - Annie Schmid-Alliana
- Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France
| |
Collapse
|
3
|
Mañas-Torres MC, Gila-Vilchez C, Vazquez-Perez FJ, Kuzhir P, Momier D, Scimeca JC, Borderie A, Goracci M, Burel-Vandenbos F, Blanco-Elices C, Rodriguez IA, Alaminos M, de Cienfuegos LÁ, Lopez-Lopez MT. Injectable Magnetic-Responsive Short-Peptide Supramolecular Hydrogels: Ex Vivo and In Vivo Evaluation. ACS Appl Mater Interfaces 2021; 13:49692-49704. [PMID: 34645258 PMCID: PMC8554763 DOI: 10.1021/acsami.1c13972] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
The inclusion of magnetic nanoparticles (MNP) in a hydrogel matrix to produce magnetic hydrogels has broadened the scope of these materials in biomedical research. Embedded MNP offer the possibility to modulate the physical properties of the hydrogel remotely and on demand by applying an external magnetic field. Moreover, they enable permanent changes in the mechanical properties of the hydrogel, as well as alterations in the micro- and macroporosity of its three-dimensional (3D) structure, with the associated potential to induce anisotropy. In this work, the behavior of biocompatible and biodegradable hydrogels made with Fmoc-diphenylalanine (Fmoc-FF) (Fmoc = fluorenylmethoxycarbonyl) and Fmoc-arginine-glycine-aspartic acid (Fmoc-RGD) short peptides to which MNP were incorporated was studied in detail with physicochemical, mechanical, and biological methods. The resulting hybrid hydrogels showed enhance mechanical properties and withstood injection without phase disruption. In mice, the hydrogels showed faster and improved self-healing properties compared to their nonmagnetic counterparts. Thanks to these superior physical properties and stability during culture, they can be used as 3D scaffolds for cell growth. Additionally, magnetic short-peptide hydrogels showed good biocompatibility and the absence of toxicity, which together with their enhanced mechanical stability and excellent injectability make them ideal biomaterials for in vivo biomedical applications with minimally invasive surgery. This study presents a new approach to improving the physical and mechanical properties of supramolecular hydrogels by incorporating MNP, which confer structural reinforcement and stability, remote actuation by magnetic fields, and better injectability. Our approach is a potential catalyst for expanding the biomedical applications of supramolecular short-peptide hydrogels.
Collapse
Affiliation(s)
- Mari C. Mañas-Torres
- Universidad
de Granada, Departamento de Química Orgánica, Facultad
de Ciencias, Unidad de Excelencia de Química
Aplicada a Biomedicina y Medioambiente, 18071 Granada, Spain
- Instituto
de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
| | - Cristina Gila-Vilchez
- Universidad
de Granada, Departamento de
Física Aplicada, Facultad de Ciencias, 18071 Granada, Spain
- Instituto
de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
| | | | - Pavel Kuzhir
- Université
Côte d’Azur, CNRS UMR 7010, Institute of Physics of Nice, Parc Valrose, 06108 Nice, France
| | - David Momier
- Université
Côte d’Azur, CNRS UMR 7277, Institute of Biology Valrose, 06107 Nice, France
| | - Jean-Claude Scimeca
- Université
Côte d’Azur, CNRS UMR 7277, Institute of Biology Valrose, 06107 Nice, France
| | - Arnaud Borderie
- Université
Côte d’Azur, Department of Pathology, CHU Nice, 06107 Nice, France
| | - Marianne Goracci
- Université
Côte d’Azur, Department of Pathology, CHU Nice, 06107 Nice, France
| | | | - Cristina Blanco-Elices
- Instituto
de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
- University
of Granada, Department of Histology and
Tissue Engineering Group, Faculty of Medicine, 18071 Granada, Spain
| | - Ismael A. Rodriguez
- University
of Granada, Department of Histology and
Tissue Engineering Group, Faculty of Medicine, 18071 Granada, Spain
- Department
of Histology, Faculty of Dentistry, National
University of Cordoba, 5000 Cordoba, Argentina
| | - Miguel Alaminos
- Instituto
de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
- University
of Granada, Department of Histology and
Tissue Engineering Group, Faculty of Medicine, 18071 Granada, Spain
| | - Luis Álvarez de Cienfuegos
- Universidad
de Granada, Departamento de Química Orgánica, Facultad
de Ciencias, Unidad de Excelencia de Química
Aplicada a Biomedicina y Medioambiente, 18071 Granada, Spain
- Instituto
de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
| | - Modesto T. Lopez-Lopez
- Universidad
de Granada, Departamento de
Física Aplicada, Facultad de Ciencias, 18071 Granada, Spain
- Instituto
de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
| |
Collapse
|
4
|
Gulati K, Scimeca JC, Ivanovski S, Verron E. Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants. Drug Discov Today 2021; 26:2734-2742. [PMID: 34246772 DOI: 10.1016/j.drudis.2021.07.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 06/25/2021] [Accepted: 07/02/2021] [Indexed: 02/06/2023]
Abstract
Titanium-based orthopaedic/dental implants modified with various metal-doping strategies can enhance local therapy and bioactivity. Intentional or unintentional (because of loading and wear) release of metal ions/nanoparticles (NPs) from metal-doped implants can be therapeutic or cause adverse local tissue reactions, compromising long-term survival. Strategies to incorporate metals into implants, such as superficial or deep loading inside nano-engineered surfaces, including nanotubes, and the physiochemical characteristics of the released species significantly influence both their therapeutic and cytotoxic potential. In this review, we compare and contrast this 'double-edged sword' to arrive at an improved understanding of metal-doped implants to enable controlled therapy while minimising cytotoxicity concerns.
Collapse
Affiliation(s)
- Karan Gulati
- The University of Queensland, School of Dentistry, Herston, QLD 4006, Australia
| | | | - Sašo Ivanovski
- The University of Queensland, School of Dentistry, Herston, QLD 4006, Australia
| | - Elise Verron
- Université de Nantes, CNRS, UMR 6230, CEISAM, UFR Sciences et Techniques, 2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France.
| |
Collapse
|
5
|
Jing L, Rota S, Olivier F, Momier D, Guigonis JM, Schaub S, Samson M, Bouler JM, Scimeca JC, Rochet N, Lagadec P. Proteomic analysis identified LBP and CD14 as key proteins in blood/biphasic calcium phosphate microparticle interactions. Acta Biomater 2021; 127:298-312. [PMID: 33831568 DOI: 10.1016/j.actbio.2021.03.070] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Revised: 03/03/2021] [Accepted: 03/31/2021] [Indexed: 12/25/2022]
Abstract
Immediately upon implantation, scaffolds for bone repair are exposed to the patient's blood. Blood proteins adhere to the biomaterial surface and the protein layer affects both blood cell functions and biomaterial bioactivity. Previously, we reported that 80-200 µm biphasic calcium phosphate (BCP) microparticles embedded in a blood clot, induce ectopic woven bone formation in mice, when 200-500 µm BCP particles induce mainly fibrous tissue. Here, in a LC-MS/MS proteomic study we compared the differentially expressed blood proteins (plasma and blood cell proteins) and the deregulated signaling pathways of these osteogenic and fibrogenic blood composites. We showed that blood/BCP-induced osteogenesis is associated with a higher expression of fibrinogen (FGN) and an upregulation of the Myd88- and NF-κB-dependent TLR4 signaling cascade. We also highlighted the key role of the LBP/CD14 proteins in the TLR4 activation of blood cells by BCP particles. As FGN is an endogenous ligand of TLR4, able to modulate blood composite stiffness, we propose that different FGN concentrations modify the blood clot mechanical properties, which in turn modulate BCP/blood composite osteoactivity through TLR4 signaling. The present findings provide an insight at the protein level, into the mechanisms leading to an efficient bone reconstruction by blood/BCP composites. STATEMENT OF SIGNIFICANCE: Upon implantation, scaffolds for bone repair are exposed to the patient's blood. Blood proteins adhere to bone substitute surface and this protein layer affects both biomaterial bioactivity and bone healing. Therefore, for the best outcome for patients, it is crucial to understand the molecular interactions between blood and bone scaffolds. Biphasic calcium phosphate (BCP) ceramics are considered as the gold standard in bone reconstruction surgery. Here, using proteomic analyses we showed that the osteogenic properties of 80-200 µm BCP particles embedded in a blood clot is associated with a higher expression of fibrinogen. Fibrinogen upregulates the Myd88- and NF-κB-dependent TLR4 pathway in blood cells and, BCP-induced TLR4 activation is mediated by the LBP and CD14 proteins.
Collapse
|
6
|
Vidal F, Lopez P, Lopez-Fernandez LA, Ranc F, Scimeca JC, Cuzin F, Rassoulzadegan M. Expression of Concern: Gene trap analysis of germ cell signaling to Sertoli cells: NGF-TrkA mediated induction of Fra1 and Fos by post-meiotic germ cells. J Cell Sci 2019; 132:132/10/jcs233692. [PMID: 31092634 DOI: 10.1242/jcs.233692] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Amoretti N, Diego P, Amélie P, Andreani O, Foti P, Schmid-Antomarchi H, Scimeca JC, Boileau P. Percutaneous vertebroplasty in tumoral spinal fractures with posterior vertebral wall involvement: Feasibility and safety. Eur J Radiol 2018; 104:38-42. [PMID: 29857864 DOI: 10.1016/j.ejrad.2018.04.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Revised: 02/07/2018] [Accepted: 04/06/2018] [Indexed: 11/30/2022]
Abstract
PURPOSE to evaluate the technical feasibility and safety of CT and fluoroscopy guided percutaneous vertebroplasty in the treatment of tumoral vertebral fractures with posterior wall involvement. MATERIALS AND METHODS Institutional review board approval and informed consent were obtained for this study. Sixty-three consecutive adult patients (35 women, 28 men; mean age+/- standard deviation: 69 years+/- 14) with tumoral spinal fractures that compromised the posterior wall were treated by means of percutaneous vertebroplasty with CT and fluoroscopy guidance. Only local anesthesia was used during these procedures. Postoperative outcome was assessed using the Kostuik index. RESULTS Sixty-three vertebroplasties were performed on thirty-four thoracic (54%), twenty-six lumbar (41%), and three (5%) cervical vertebrae. The etiologies of the fractures were metastasis in twenty-eight (44%), myeloma in twenty-five (40%) and hemangioma in ten (16%). Almost all fractures (94%) were consolidated after vertebroplasty (score of Kostuik <3) (p < 0.001). No major complications were reported in our series of cases. CONCLUSION This study suggests that tumoral spinal fractures with posterior vertebral wall involvement can be successfully and safely treated by CT- and fluoroscopy-guided percutaneous vertebroplasty.
Collapse
Affiliation(s)
- Nicolas Amoretti
- Diagnostic and Interventional Radiology Unit, Nice University Hospital, 30 Voie Romaine, 06000 Nice, France.
| | - Palominos Diego
- Diagnostic and Interventional Radiology Unit, Nice University Hospital, 30 Voie Romaine, 06000 Nice, France
| | - Pellegrin Amélie
- Diagnostic and Interventional Radiology Unit, Nice University Hospital, 30 Voie Romaine, 06000 Nice, France
| | - Olivier Andreani
- Diagnostic and Interventional Radiology Unit, Nice University Hospital, 30 Voie Romaine, 06000 Nice, France
| | - Pauline Foti
- Diagnostic and Interventional Radiology Unit, Nice University Hospital, 30 Voie Romaine, 06000 Nice, France
| | - Heidy Schmid-Antomarchi
- Institut de Biologie Valrose, Université cote d'azur, Tour Pasteur, UFR Médecine, 28 Ave de Valombrose, 06107 Nice Cedex 2, France
| | - Jean-Claude Scimeca
- Institut de Biologie Valrose, Université cote d'azur, Tour Pasteur, UFR Médecine, 28 Ave de Valombrose, 06107 Nice Cedex 2, France
| | - Pascal Boileau
- Orthopaedic Surgery Unit, Nice University Hospital, 30 Voie Romaine, 06000 Nice, France
| |
Collapse
|
8
|
Le Ferrec M, Mellier C, Boukhechba F, Le Corroller T, Guenoun D, Fayon F, Montouillout V, Despas C, Walcarius A, Massiot D, Lefèvre FX, Robic C, Scimeca JC, Bouler JM, Bujoli B. Design and properties of a novel radiopaque injectable apatitic calcium phosphate cement, suitable for image-guided implantation. J Biomed Mater Res B Appl Biomater 2017; 106:2786-2795. [PMID: 29226553 DOI: 10.1002/jbm.b.34059] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 11/09/2017] [Accepted: 11/18/2017] [Indexed: 12/12/2022]
Abstract
An injectable purely apatitic calcium phosphate cement (CPC) was successfully combined to a water-soluble radiopaque agent (i.e., Xenetix® ), to result in an optimized composition that was found to be as satisfactory as poly(methyl methacrylate) (PMMA) formulations used for vertebroplasty, in terms of radiopacity, texture and injectability. For that purpose, the Xenetix dosage in the cement paste was optimized by injection of the radiopaque CPC in human cadaveric vertebrae under classical PMMA vertebroplasty conditions, performed by interventional radiologists familiar with this surgical procedure. When present in the cement paste up to 70 mg I mL-1 , Xenetix did not influence the injectability, cohesion, and setting time of the resulting composite. After hardening of the material, the same observation was made regarding the microstructure, mechanical strength and alpha-tricalcium phosphate to calcium deficient apatite transformation rate. Upon implantation in bone in a small animal model (rat), the biocompatibility of the Xenetix-containing CPC was evidenced. Moreover, an almost quantitative release of the contrast agent was found to occur rapidly, on the basis of in vitro static and dynamic quantitative studies simulating in vivo implantation. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 2786-2795, 2018.
Collapse
Affiliation(s)
- Myriam Le Ferrec
- Graftys SA, Eiffel Park, Bâtiment D, Pôle d'activités d'Aix en Provence, 13854 Aix en Provence CEDEX 3, France
| | - Charlotte Mellier
- Graftys SA, Eiffel Park, Bâtiment D, Pôle d'activités d'Aix en Provence, 13854 Aix en Provence CEDEX 3, France
| | - Florian Boukhechba
- Graftys SA, Eiffel Park, Bâtiment D, Pôle d'activités d'Aix en Provence, 13854 Aix en Provence CEDEX 3, France
| | - Thomas Le Corroller
- Hôpitaux Sud - Hôpital Sainte-Marguerite, CHU APHM, 13274, Marseille Cedex 9, France
| | - Daphné Guenoun
- Hôpitaux Sud - Hôpital Sainte-Marguerite, CHU APHM, 13274, Marseille Cedex 9, France
| | - Franck Fayon
- CNRS, UPR 3079, CEMHTI, 45071, Orléans Cedex 02, France
| | | | - Christelle Despas
- Université de Lorraine, CNRS, UMR 7564, LCPME, 54600, Villers-lès-Nancy, France
| | - Alain Walcarius
- Université de Lorraine, CNRS, UMR 7564, LCPME, 54600, Villers-lès-Nancy, France
| | | | - François-Xavier Lefèvre
- Université de Nantes, CNRS, UMR 6230, CEISAM, UFR Sciences et Techniques, BP 92208, 44322, NANTES Cedex 3, France
| | | | - Jean-Claude Scimeca
- Université Côte d'Azur, CNRS, Inserm, iBV, UMR 7277, Tour Pasteur, UFR Médecine, 06107, Nice Cedex 02, France
| | - Jean-Michel Bouler
- Université de Nantes, CNRS, UMR 6230, CEISAM, UFR Sciences et Techniques, BP 92208, 44322, NANTES Cedex 3, France
| | - Bruno Bujoli
- Université de Nantes, CNRS, UMR 6230, CEISAM, UFR Sciences et Techniques, BP 92208, 44322, NANTES Cedex 3, France
| |
Collapse
|
9
|
Strazic-Geljic I, Guberovic I, Didak B, Schmid-Antomarchi H, Schmid-Alliana A, Boukhechba F, Bouler JM, Scimeca JC, Verron E. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases. Biochem Pharmacol 2016; 116:11-21. [DOI: 10.1016/j.bcp.2016.06.020] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Accepted: 06/30/2016] [Indexed: 11/29/2022]
|
10
|
Bouvet-Gerbettaz S, Boukhechba F, Balaguer T, Schmid-Antomarchi H, Michiels JF, Scimeca JC, Rochet N. Adaptive Immune Response Inhibits Ectopic Mature Bone Formation Induced by BMSCs/BCP/Plasma Composite in Immune-Competent Mice. Tissue Eng Part A 2014; 20:2950-62. [DOI: 10.1089/ten.tea.2013.0633] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Affiliation(s)
- Sébastien Bouvet-Gerbettaz
- UFR Médecine F-06107, Université Nice Sophia Antipolis, Nice, France
- UFR Odontologie F-06357, Université Nice Sophia Antipolis, Nice, France
| | - Florian Boukhechba
- UFR Médecine F-06107, Université Nice Sophia Antipolis, Nice, France
- CNRS, UMR7277, F-06108 Nice, France
- Inserm U1091, F-06108 Nice, France
| | - Thierry Balaguer
- UFR Médecine F-06107, Université Nice Sophia Antipolis, Nice, France
- CNRS, UMR7277, F-06108 Nice, France
- Inserm U1091, F-06108 Nice, France
- Service de Chirurgie Plastique, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Heidy Schmid-Antomarchi
- UFR Médecine F-06107, Université Nice Sophia Antipolis, Nice, France
- CNRS, UMR7277, F-06108 Nice, France
- Inserm U1091, F-06108 Nice, France
| | - Jean-François Michiels
- UFR Médecine F-06107, Université Nice Sophia Antipolis, Nice, France
- Service d'Anatomopathologie, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Jean-Claude Scimeca
- UFR Médecine F-06107, Université Nice Sophia Antipolis, Nice, France
- CNRS, UMR7277, F-06108 Nice, France
- Inserm U1091, F-06108 Nice, France
| | - Nathalie Rochet
- UFR Médecine F-06107, Université Nice Sophia Antipolis, Nice, France
- CNRS, UMR7277, F-06108 Nice, France
- Inserm U1091, F-06108 Nice, France
| |
Collapse
|
11
|
Verron E, Schmid-Antomarchi H, Pascal-Mousselard H, Schmid-Alliana A, Scimeca JC, Bouler JM. Therapeutic strategies for treating osteolytic bone metastases. Drug Discov Today 2014; 19:1419-26. [PMID: 24742971 DOI: 10.1016/j.drudis.2014.04.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2013] [Revised: 03/11/2014] [Accepted: 04/07/2014] [Indexed: 01/15/2023]
Abstract
The recent progress in oncologic management of patients with localized cancer or metastatic disease has permitted a significant improvement in life expectancy. Nevertheless, bone metastases and their consequent skeletal-related events (SREs) are still associated with unfavorable prognosis and greatly affect quality of life. Global management of these bone metastases includes traditional local approaches (surgery, radiotherapy, etc.) and systemic administration of chemotherapeutic agents. This review focuses on treatments specific for bone metastases and, in particular, on inhibitors of bone resorption that are effective for preventing and delaying the development of SREs.
Collapse
Affiliation(s)
- Elise Verron
- INSERM U791, Université de Nantes, Faculté de Chirurgie Dentaire, 44042 Nantes, France.
| | | | | | - Annie Schmid-Alliana
- Univ Nice Sophia Antipolis, CNRS, iBV, UMR7277, UFR Médecine, 06107 Nice Cedex 2, France
| | - Jean-Claude Scimeca
- Univ Nice Sophia Antipolis, CNRS, iBV, UMR7277, UFR Médecine, 06107 Nice Cedex 2, France
| | - Jean-Michel Bouler
- INSERM U791, Université de Nantes, Faculté de Chirurgie Dentaire, 44042 Nantes, France
| |
Collapse
|
12
|
Mouline CC, Beranger GE, Schmid-Antomarchi H, Quincey D, Momier D, Boukhechba F, Carle GF, Rochet N, Scimeca JC. Monocytes differentiation upon treatment with a peptide corresponding to the C-terminus of activated T cell-expressed Tirc7 protein. J Cell Physiol 2012; 227:3088-98. [PMID: 22015593 DOI: 10.1002/jcp.23059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Atp6v0a3 gene encodes for two alternative products, Tirc7 and a3 proteins, which are differentially expressed in activated T cells and resorbing osteoclasts, respectively. Tirc7 plays a central role in T cell activation, while a3 protein is critical for osteoclast-mediated bone matrix resorption. Based on the large body of evidences documenting the relationships between T cells and osteoclasts, we hypothesized that the extracellular C-terminus of Tirc7 protein could directly interact with osteoclast precursor cells. To address this issue, we performed the molecular cloning of a mouse Atp6v0a3 cDNA segment encoding the last 40 amino acids of Tirc7 protein, and we used this peptide as a ligand added to mouse osteoclast precursor cells. We evidenced that Tirc7-Cter peptide induced the differentiation of RAW264.7 cells into osteoclast-like cells, stimulated an autocrine/paracrine regulatory loop potentially involved in osteoclastic differentiation control, and strongly up-regulated F4/80 protein expression within multinucleated osteoclast-like cells. Using a mouse bone marrow-derived CD11b(+) cell line, or total bone marrow primary cells, we observed that similarly to Rankl, Tirc7-Cter peptide induced the formation of TRACP-positive large multinucleated cells. At last, using mouse primary monocytes purified from total bone marrow, we determined that Tirc7-Cter peptide induced the appearance of small multinucleated cells (3-4 nuclei), devoid of resorbing activity, and which displayed modulations of dendritic cell marker genes expression. In conclusion, we report for the first time on biological effects mediated by a peptide corresponding to the C-terminus of Tirc7 protein, which interfere with monocytic differentiation pathways.
Collapse
Affiliation(s)
- Caroline C Mouline
- GéPITOs, Université de Nice, CNRS, UMR 6235, UFR Médecine, NICE, Cedex 2, France
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Verron E, Loubat A, Carle GF, Vignes-Colombeix C, Strazic I, Guicheux J, Rochet N, Bouler JM, Scimeca JC. Molecular effects of gallium on osteoclastic differentiation of mouse and human monocytes. Biochem Pharmacol 2011; 83:671-9. [PMID: 22202439 DOI: 10.1016/j.bcp.2011.12.015] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2011] [Revised: 12/12/2011] [Accepted: 12/12/2011] [Indexed: 10/14/2022]
Abstract
We had previously reported that gallium (Ga) inhibited both the differentiation and resorbing activity of osteoclasts in a dose-dependent manner. To provide new insights into Ga impact on osteoclastogenesis, we investigated here the molecular mechanisms of Ga action on osteoclastic differentiation of monocytes upon Rankl treatment. We first observed that Ga treatment inhibited the expression of Rankl-induced early differentiation marker genes, while the same treatment performed subsequently did not modify the expression of late differentiation marker genes. Focusing on the early stages of osteoclast differentiation, we observed that Ga considerably disturbed both the initial induction as well as the autoamplification step of Nfatc1 gene. We next demonstrated that Ga strongly up-regulated the expression of Traf6, p62 and Cyld genes, and we observed concomitantly an inhibition of IκB degradation and a blockade of NFκB nuclear translocation, which regulates the initial induction of Nfatc1 gene expression. In addition, Ga inhibited c-Fos gene expression, and subsequently the auto-amplification stage of Nfatc1 gene expression. Lastly, considering calcium signaling, we observed upon Ga treatment an inhibition of calcium-induced Creb phosphorylation, as well as a blockade of gadolinium-induced calcium entry through TRPV-5 calcium channels. We identify for the first time Traf6, p62, Cyld, IκB, NFκB, c-Fos, and the calcium-induced Creb phosphorylation as molecular targets of Ga, this tremendously impacting the expression of the master transcription factor Nfatc1. In addition, our results strongly suggest that the TRPV-5 calcium channel, which is located within the plasma membrane, is a target of Ga action on human osteoclast progenitor cells.
Collapse
Affiliation(s)
- E Verron
- GéPITOs, Université de Nice, CNRS, UMR 6235, UFR Médecine, 28 Avenue de Valombrose, 06107 Nice, Cedex 2, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Boukhechba F, Balaguer T, Bouvet-Gerbettaz S, Michiels JF, Bouler JM, Carle GF, Scimeca JC, Rochet N. Fate of bone marrow stromal cells in a syngenic model of bone formation. Tissue Eng Part A 2011; 17:2267-78. [PMID: 21539494 DOI: 10.1089/ten.tea.2010.0461] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Bone marrow stromal cells (BMSCs) have been demonstrated to induce bone formation when associated to osteoconductive biomaterials and implanted in vivo. Nevertheless, their role in bone reconstruction is not fully understood and rare studies have been conducted to follow their destiny after implantation in syngenic models. The aim of the present work was to use sensitive and quantitative methods to track donor and recipient cells after implantation of BMSCs in a syngenic model of ectopic bone formation. Using polymerase chain reaction (PCR) amplification of the Sex determining Region Y (Sry) gene and in situ hybridization of the Y chromosome in parallel to histological analysis, we have quantified within the implants the survival of the donor cells and the colonization by the recipient cells. The putative migration of the BMSCs in peripheral organs was also analyzed. We show here that grafted cells do not survive more than 3 weeks after implantation and might migrate in peripheral lymphoid organs. These cells are responsible for the attraction of host cells within the implants, leading to the centripetal colonization of the biomaterial by new bone.
Collapse
Affiliation(s)
- Florian Boukhechba
- GEPITOS, Université Nice Sophia-Antipolis, CNRS, UFR de Médecine, Nice, France
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Mouline CC, Quincey D, Laugier JP, Carle GF, Bouler JM, Rochet N, Scimeca JC. Osteoclastic differentiation of mouse and human monocytes in a plasma clot/biphasic calcium phosphate microparticles composite. Eur Cell Mater 2010; 20:379-92. [PMID: 21154244 DOI: 10.22203/ecm.v020a31] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
We recently demonstrated that blood clotted around biphasic calcium phosphate (BCP) microparticles constituted a composite biomaterial that could be used for bone defect filling. In addition, we showed that mononuclear cells, i.e. monocytes and lymphocytes, play a central role in the osteogenic effect of this biomaterial. Hypothesizing that osteoclast progenitors could participate to the pro-osteogenic effect of mononuclear cells we observed previously, we focus on this population through the study of mouse monocyte/macrophage cells (RAW264.7 cell line), as well as human pre-osteoclastic cells derived from mononuclear hematopoietic progenitor cells (monocytes-enriched fraction from peripheral blood). Using monocyte-derived osteoclast progenitors cultured within plasma clot/BCP microparticles composite, we aimed in the present report at the elucidation of transcriptional profiles of genes related to osteoclastogenesis and to bone remodelling. For both human and mouse monocytes, real-time PCR experiments demonstrated that plasma clot/BCP scaffold potentiated the expression of marker genes of the osteoclast differentiation such as Nfactc1, Jdp2, Fra2, Tracp and Ctsk. By contrast, Mmp9 was induced in mouse but not in human cells, and Ctr expression was down regulated for both species. In addition, for both mouse and human precursors, osteoclastic differentiation was associated with a strong stimulation of VegfC and Sdf1 genes expression. At last, using field-emission scanning electron microscopy analysis, we observed the interactions between human monocytes and BCP microparticles. As a whole, we demonstrated that plasma clot/BCP microparticles composite provided monocytes with a suitable microenvironment allowing their osteoclastic differentiation, together with the production of pro-angiogenic and chemoattractant factors.
Collapse
Affiliation(s)
- Caroline C Mouline
- GéPITOs, UMR6235 UFR de Médecine, 28 Avenue de Valombrose, F-06107 NICE, Cedex 2, France
| | | | | | | | | | | | | |
Collapse
|
16
|
Balaguer T, Boukhechba F, Clavé A, Bouvet-Gerbettaz S, Trojani C, Michiels JF, Laugier JP, Bouler JM, Carle GF, Scimeca JC, Rochet N. Biphasic Calcium Phosphate Microparticles for Bone Formation: Benefits of Combination with Blood Clot. Tissue Eng Part A 2010; 16:3495-505. [DOI: 10.1089/ten.tea.2010.0227] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Affiliation(s)
- Thierry Balaguer
- GEPITOS, Université Nice Sophia-Antipolis, CNRS, UFR de Médecine, Nice, France
- Service de Chirurgie Plastique, Réparatrice et Esthétique, Chirurgie de la Main, Centre Hospitalier Universitaire de Nice, Hôpital St. Roch, Nice, France
| | - Florian Boukhechba
- GEPITOS, Université Nice Sophia-Antipolis, CNRS, UFR de Médecine, Nice, France
| | - Arnaud Clavé
- GEPITOS, Université Nice Sophia-Antipolis, CNRS, UFR de Médecine, Nice, France
| | | | - Christophe Trojani
- GEPITOS, Université Nice Sophia-Antipolis, CNRS, UFR de Médecine, Nice, France
- Service de Chirurgie Orthopédique, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Jean-François Michiels
- Service d'Anatomopathologie, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Jean-Pierre Laugier
- Centre Commun de Microscopie Appliquée, Université de Nice-Sophia Antipolis, UFR Sciences, Nice, France
| | - Jean-Michel Bouler
- LIOAD, Université de Nantes, INSERM UMR 791, UFR d'Odontologie de Nantes, Nantes, France
| | - Georges F. Carle
- GEPITOS, Université Nice Sophia-Antipolis, CNRS, UFR de Médecine, Nice, France
| | - Jean-Claude Scimeca
- GEPITOS, Université Nice Sophia-Antipolis, CNRS, UFR de Médecine, Nice, France
| | - Nathalie Rochet
- GEPITOS, Université Nice Sophia-Antipolis, CNRS, UFR de Médecine, Nice, France
| |
Collapse
|
17
|
Verron E, Masson M, Khoshniat S, Duplomb L, Wittrant Y, Baud'huin M, Badran Z, Bujoli B, Janvier P, Scimeca JC, Bouler JM, Guicheux J. Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts. Br J Pharmacol 2010; 159:1681-92. [PMID: 20397300 DOI: 10.1111/j.1476-5381.2010.00665.x] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND AND PURPOSE Gallium (Ga) has been shown to be effective in the treatment of disorders associated with accelerated bone loss, including cancer-related hypercalcemia and Paget's disease. These clinical applications suggest that Ga could reduce bone resorption. However, few studies have studied the effects of Ga on osteoclastic resorption. Here, we have explored the effects of Ga on bone cells in vitro. EXPERIMENTAL APPROACH In different osteoclastic models [osteoclasts isolated from long bones of neonatal rabbits (RBC), murine RAW 264.7 cells and human CD14-positive cells], we have performed resorption activity tests, staining for tartrate resistant acid phosphatase (TRAP), real-time polymerase chain reaction analysis, viability and apoptotic assays. We also evaluated the effect of Ga on osteoblasts in terms of proliferation, viability and activity by using an osteoblastic cell line (MC3T3-E1) and primary mouse osteoblasts. KEY RESULTS Gallium dose-dependently (0-100 microM) inhibited the in vitro resorption activity of RBC and induced a significant decrease in the expression level of transcripts coding for osteoclastic markers in RAW 264.7 cells. Ga also dramatically reduced the formation of TRAP-positive multinucleated cells. Ga down-regulated in a dose-dependant manner the expression of the transcription factor NFATc1. However, Ga did not affect the viability or activity of primary and MC3T3-E1 osteoblasts. CONCLUSIONS AND IMPLICATIONS Gallium exhibits a dose-dependent anti-osteoclastic effect by reducing in vitro osteoclastic resorption, differentiation and formation without negatively affecting osteoblasts. We provide evidence that this inhibitory mechanism involves down-regulation of NFATc1 expression, a master regulator of RANK-induced osteoclastic differentiation.
Collapse
|
18
|
Moya A, Tambutté S, Béranger G, Gaume B, Scimeca JC, Allemand D, Zoccola D. Cloning and use of a coral 36B4 gene to study the differential expression of coral genes between light and dark conditions. Mar Biotechnol (NY) 2008; 10:653-663. [PMID: 18425549 DOI: 10.1007/s10126-008-9101-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2007] [Revised: 02/19/2008] [Accepted: 03/17/2008] [Indexed: 05/26/2023]
Abstract
This paper aims to validate reference genes for gene expression studies between light and dark conditions in the scleractinian coral Stylophora pistillata for future gene expression studies of the "light-enhanced calcification" phenomenon. For this purpose, we cloned, sequenced, and characterized a candidate reference gene, the 36B4 gene from the coral S. pistillata, and validated 36B4 and beta-actin as reference genes. To illustrate the future applications of these reference genes, we tested the dark and light expression of two photosynthetic genes (Rubisco and D1 protein of the photosystem II) and two genes encoding proteins involved in calcium transport for coral calcification (a calcium ATPase and a calcium channel). Results show that both photosynthetic genes are enhanced during the light when standardized against 36B4 and beta-actin, whereas the two genes encoding proteins involved in calcium transport are not differentially expressed between light and dark conditions. The characterization of a coral 36B4 and the establishment of such valid reference genes will be useful for future gene expression studies between diverse conditions (aposymbiotic/symbiotic, stress/control, light/dark conditions) in scleractinian corals.
Collapse
Affiliation(s)
- Aurélie Moya
- Centre Scientifique de Monaco, Avenue Saint-Martin, MC-98000, Monaco, Principality of Monaco
| | | | | | | | | | | | | |
Collapse
|
19
|
Beranger GE, Momier D, Guigonis JM, Samson M, Carle GF, Scimeca JC. Differential binding of poly(ADP-Ribose) polymerase-1 and JunD/Fra2 accounts for RANKL-induced Tcirg1 gene expression during osteoclastogenesis. J Bone Miner Res 2007; 22:975-83. [PMID: 17419679 DOI: 10.1359/jbmr.070406] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
UNLABELLED We studied Tcirg1 gene expression on RANKL-induced osteoclastic differentiation of the mouse model RAW264.7 cells. We identified a mechanism involving PARP-1 inhibition release and JunD/Fra-2 binding, which is responsible for Tcirg1 gene upregulation. INTRODUCTION The Tcirg1 gene encodes the a3 isoform of the V-ATPase a subunit, which plays a critical role in the resorption activity of the osteoclast. Using serial deletion constructs of the Tcirg1 gene promoter, we performed a transcriptional study to identify factor(s) involved in the regulation of the RANKL-induced gene expression. MATERIALS AND METHODS The promoter activity of serial-deletion fragments of the Tcirg1 gene promoter was monitored throughout the RAW264.7 cells differentiation process. We next performed sequence analysis, EMSA, UV cross-linking, qPCR, and gel supershift experiments to identify the factor(s) interacting with the promoter. RESULTS A deletion of the -1297-1244 region led to the disappearance of the RANKL-induced promoter activity. EMSA experiments showed the binding of two factors that undergo differential binding on RANKL treatment. Supershift experiments led us to identify the dimer JunD/Fra-2 as the binding activity associated with the -1297/-1268 Tcirg1 gene promoter sequence in response to RANKL. Moreover, we observed poly(ADP-ribose) polymerase-1 (PARP-1) binding to an adjacent site (-1270/-1256), and this interaction was disrupted after RANKL treatment. CONCLUSIONS We provide data that identify junD proto-oncogene (JunD) and Fos-related antigen 2 (Fra-2) as the activator protein-1 (AP-1) factors responsible for the RANKL-induced upregulation of the mouse Tcirg1 gene expression. Moreover, we identified another binding site for PARP-1 that might account for the repression of Tcirg1 gene expression in pre-osteoclastic cells.
Collapse
|
20
|
Beranger GE, Momier D, Rochet N, Quincey D, Guigonis JM, Samson M, Carle GF, Scimeca JC. RANKL treatment releases the negative regulation of the poly(ADP-ribose) polymerase-1 on Tcirg1 gene expression during osteoclastogenesis. J Bone Miner Res 2006; 21:1757-69. [PMID: 17002555 DOI: 10.1359/jbmr.060809] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
UNLABELLED The Tcirg1 gene encodes the osteoclast-specific a3 isoform of the V-ATPase a subunit. Using the mouse osteoclastic model RAW264.7 cells, we studied Tcirg1 gene expression, and we identified PARP-1 as a transcriptional repressor negatively regulated by RANKL during osteoclastogenesis. INTRODUCTION The TCIRG1 gene encodes the a3 isoform of the V-ATPase a subunit, and mutations at this locus account for approximately 60% of infantile malignant osteopetrosis cases. Using RAW264.7 cells as an osteoclastic differentiation model, we undertook a transcriptional study of the mouse Tcirg1 gene focused on the 4-kb region upstream of the transcription starting point. MATERIALS AND METHODS The promoter activity of serial-deletion fragments of the Tcirg1 gene promoter was monitored throughout the RAW264.7 cell differentiation process. We next performed EMSA, UV cross-linking, affinity purification, mass spectrometry analysis, gel supershift, and siRNA transfection experiments to identify the factor(s) interacting with the promoter. RESULTS The -3946/+113 region of the mouse Tcirg1 gene displayed a high basal promoter activity, which was enhanced by RANKL treatment of RAW264.7 cells. Constructs deleted up to -1589 retained this response to RANKL. A deletion up to -1402 induced a 3-fold enhancement of the basal activity, whereas RANKL response was not affected. EMSA experiments led us to identify within the -1589/-1402 region, a 10-nucleotide sequence, which bound a nuclear protein present in nondifferentiated RAW264.7 cells. This interaction was lost using nuclear extracts derived from RANKL-treated cells. Affinity purification followed by mass spectrometry analysis and gel supershift assay allowed the identification of poly(ADP-ribose) polymerase-1 (PARP-1) as this transcriptional repressor, whereas Western blot experiments revealed the cleavage of the DNA-binding domain of PARP-1 on RANKL treatment. Finally, both PARP-1 depletion after siRNA transfection and RAW264.7 cell treatment by an inhibitor of PARP-1 activity induced an increase of a3 mRNA expression. CONCLUSIONS We provide evidence that the basal transcription activity of the Tcirg1 gene is negatively regulated by the binding of PARP-1 protein to its promoter region in mouse pre-osteoclast. On RANKL treatment, PARP-1 protein is cleaved and loses its repression effect, allowing an increase of Tcirg1 gene expression that is critical for osteoclast function.
Collapse
Affiliation(s)
- Guillaume E Beranger
- GéPITOS-K2943 CNRS/UNSA, Faculté de Médecine de l'Université de Nice-Sophia Antipolis, Nice, France
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Trojani C, Boukhechba F, Scimeca JC, Vandenbos F, Michiels JF, Daculsi G, Boileau P, Weiss P, Carle GF, Rochet N. Ectopic bone formation using an injectable biphasic calcium phosphate/Si-HPMC hydrogel composite loaded with undifferentiated bone marrow stromal cells. Biomaterials 2006; 27:3256-64. [PMID: 16510180 DOI: 10.1016/j.biomaterials.2006.01.057] [Citation(s) in RCA: 101] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2005] [Accepted: 01/24/2006] [Indexed: 11/23/2022]
Abstract
We have used a new synthetic injectable composite constituted of hydroxyapatite/tricalcium phosphate (HA/TCP) particles in suspension in a self-hardening Si-hydroxypropylmethylcellulose (HPMC) hydrogel. The aim of this study was to evaluate in vivo the biocompatibility and the new bone formation efficacy of this scaffold loaded with undifferentiated bone marrow stromal cells (BMSCs). This biomaterial was mixed extemporaneously with BMSCs prepared from C57BL/6 mice, injected in subcutaneous and intramuscular sites and retrieved 4 and 8 weeks after implantation. Dissection of the implants revealed a hard consistency and the absence of a fibrous capsule reflecting a good integration into the host tissues. Histological analysis showed mineralized woven bone in the granule inter-space with numerous active osteoclasts attached to the particles as assessed by the presence of multinucleated cells positively stained for TRAP activity and for the a3 subunit of the V-ATPase. Small vessels were homogenously distributed in the whole implants. Similar results were obtained in SC and IM sites and no bone formation was observed in the control groups when cell-free and particle-free transplants were injected. These results indicate that this injectable biphasic calcium phosphate-hydrogel composite mixed with undifferentiated BMSCs is a new promising osteoinductive bone substitute. It also provides with an original in vivo model of osteoclast differentiation and function.
Collapse
Affiliation(s)
- Christophe Trojani
- CNRS/UNSA FRE 2720, IFR50, Faculté de Médecine, Avenue de Valombrose, and Service de Chirurgie Orthopédique, Hôpital l'Archet 2, Centre Hospitalier Universitaire de Nice, 151 route Saint Antoine de Ginestière, 06202 Nice, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Zoccola D, Tambutté E, Kulhanek E, Puverel S, Scimeca JC, Allemand D, Tambutté S. Molecular cloning and localization of a PMCA P-type calcium ATPase from the coral Stylophora pistillata. Biochimica et Biophysica Acta (BBA) - Biomembranes 2004; 1663:117-26. [PMID: 15157614 DOI: 10.1016/j.bbamem.2004.02.010] [Citation(s) in RCA: 138] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/02/2003] [Revised: 02/20/2004] [Accepted: 02/27/2004] [Indexed: 11/16/2022]
Abstract
Plasma-membrane calcium pumps (PMCAs) are responsible for the expulsion of Ca(2+) from the cytosol of all eukaryotic cells and are one of the major transport systems involved in long-term regulation of resting intracellular Ca(2+) concentration. An important feature of stony corals, one of the major groups of calcifying animals, is the continuous export of large quantities of Ca(2+) for skeletogenesis. Here, we report the cloning and functional expression of the stpPMCA gene from the coral Stylophora pistillata, and whose features resemble those of the plasma-membrane Ca(2+)-ATPase family of mammalian cells. This is the first known example of a Ca(2+)-ATPase from the phylum Cnidaria, and thus, the most phylogenetically distant PMCA sequence in the animal kingdom described to date. We demonstrate that the localization of stpPMCA within calicoblastic cells is fully coherent with its role in calcification. We also show that the coral Ca(2+) pump is more closely related to vertebrate PMCAs than to Caenorhabditis elegans PMCAs. The cloning of evolutionarily conserved genes from cnidarian species repeatedly shows that these genes encode similar functional domains. Moreover, this high level of gene conservation further validates the use of cnidarian model systems for studying processes shared by Eumetazoans.
Collapse
Affiliation(s)
- Didier Zoccola
- Centre Scientifique de Monaco, Avenue Saint Martin, MC-98000, Monaco.
| | | | | | | | | | | | | |
Collapse
|
23
|
Scimeca JC, Quincey D, Parrinello H, Romatet D, Grosgeorge J, Gaudray P, Philip N, Fischer A, Carle GF. Novel mutations in the TCIRG1 gene encoding the a3 subunit of the vacuolar proton pump in patients affected by infantile malignant osteopetrosis. Hum Mutat 2003; 21:151-7. [PMID: 12552563 DOI: 10.1002/humu.10165] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Fifty percent of the infantile malignant osteopetrosis (IMO) cases reported in the literature present mutations in the TCIRG1 gene encoding the 116-kDa osteoclast specific subunit of the vacuolar proton ATPase (ATP6I). In this study, we identified four novel mutations in a series of six IMO patients. All of these mutations correspond to single nucleotide changes and affect splice acceptor or donor sites, resulting in aberrant transcription products. We report also a missense mutation, G405R, previously described in several Costa Rican patients. This independent finding suggests that the highly conserved residue at amino acid 405 plays a critical role in the a3 subunit function. Finally, the results of this study were used to provide a prenatal diagnosis to one of the families.
Collapse
MESH Headings
- Chromosomes, Human, Pair 11/genetics
- Female
- Genes, Recessive/genetics
- Genetic Markers/genetics
- Genotype
- Haplotypes/genetics
- Humans
- Infant
- Infant, Newborn
- Infant, Newborn, Diseases/diagnosis
- Infant, Newborn, Diseases/genetics
- Infant, Newborn, Diseases/mortality
- Male
- Mutation/genetics
- Organ Specificity/genetics
- Osteoclasts/classification
- Osteoclasts/metabolism
- Osteopetrosis/diagnosis
- Osteopetrosis/genetics
- Osteopetrosis/mortality
- Pedigree
- Prenatal Diagnosis
- Protein Subunits/genetics
- Vacuolar Proton-Translocating ATPases/genetics
Collapse
Affiliation(s)
- Jean-Claude Scimeca
- Instabilité et Altérations des Génomes, UMR6549 CNRS/UNSA, Faculté de Médecine de l'Université de Nice-Sophia Antipolis, Nice, France
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Santucci-Darmanin S, Vidal F, Scimeca JC, Turc-Carel C, Paquis-Flucklinger V. Family of SRY/Sox proteins is involved in the regulation of the mouse Msh4 (MutS Homolog 4) gene expression. Mol Reprod Dev 2001; 60:172-80. [PMID: 11553915 DOI: 10.1002/mrd.1074] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The eukaryotic MutHLS-like system plays a crucial role in both mitosis and meiosis. Until now, a number of works have focused on the function of MutS and MutL homologs during mismatch DNA repair. Nevertheless, little is known about the role of these proteins during meiosis. MSH4 is a meiosis specific protein that is necessary for meiotic recombination in Saccharomyces cerevisiae. The human MSH4 protein is only found in testis and ovary. It is involved first in synapsis and second during recombination together with MLH1 (MutL Homolog 1). Here, we report the identification of the mouse Msh4 gene that is located on chromosome 3. We examined the expression of mMsh4 in testes of increasing developmental age and in elutriated germ cells. The pattern of expression during spermatogenesis is consistent with a role for MSH4 both during zygonema and pachynema. We demonstrated a promoter activity of the mMsh4 5'-flanking region by cell transfection experiments with a luciferase reporter gene. We found several SRY/Sox binding sites in this region and co-transfection experiments showed that SRY could down regulate mMsh4 promoter transcriptional activity. We propose that the regulation of mMsh4 expression could be one of the reasons for the persistence of SRY and/or SRY-related proteins in adult testis.
Collapse
Affiliation(s)
- S Santucci-Darmanin
- UMR CNRS/UNSA 6549, Faculté de Médecine, Av. de Valombrose, Nice cedex, France
| | | | | | | | | |
Collapse
|
25
|
Vidal F, Lopez P, López-Fernández LA, Ranc F, Scimeca JC, Cuzin F, Rassoulzadegan M. Gene trap analysis of germ cell signaling to Sertoli cells: NGF-TrkA mediated induction of Fra1 and Fos by post-meiotic germ cells. J Cell Sci 2001; 114:435-43. [PMID: 11148144 DOI: 10.1242/jcs.114.2.435] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Analysis of complex signalisation networks involving distinct cell types is required to understand most developmental processes. Differentiation of male germ cells in adult mammals involves such a cross-talk between Sertoli cells, the somatic component which supports and controls germinal differentiation, and germ cells at their successive maturation stages. We developed a gene trapping strategy to identify genes, which, in Sertoli cells, are either up- or down-regulated by signals emitted by the germinal component. A library of approximately 2,000 clones was constituted from colonies independently selected from the Sertoli line 15P-1 by growth in drug-containing medium after random integration of a promoter-less (beta)geo transgene (neo(r)-lacZ fusion), which will be expressed as a fusion transcript from a ‘trapped’ cellular promoter, different in each clone. A first screen conducted on 700 events identified six clones in which beta-galactosidase activity was increased and one in which it was repressed upon addition of germ cells. The targeted loci were identified by cloning and sequencing the genomic region 5′ of the insert. One of them was identified as the gene encoding Fra1, a component of the AP1 transcription regulatory complex. Accumulation of Fra1 mRNA was induced, both in 15P-1 and in freshly explanted Sertoli cells, by addition of either round spermatids or nerve growth factor (NGF). The effect of NGF was mediated by the TrkA receptor and the ERK1-ERK2 kinase kinase pathway. Fos and Fra1 transcription were induced within the first hour after addition of the neurotrophin, but, unlike what is observed after serum induction in the same cells, a second wave of transcription of Fra1, but not of Fos, started 16 hours later and peaked at higher levels at about 20 hours. These results suggest that AP1 activation may be an important relay in the Sertoli-germ cell cross-talk, and validate the gene trapping approach as a tool for the identification of target genes in cell culture systems.
Collapse
Affiliation(s)
- F Vidal
- Unité 470 de l'Institut National de la Santé et de la Recherche Médicale and Unité Mixte CNRS-Université 6549, Université de Nice, France
| | | | | | | | | | | | | |
Collapse
|
26
|
Scimeca JC, Franchi A, Trojani C, Parrinello H, Grosgeorge J, Robert C, Jaillon O, Poirier C, Gaudray P, Carle GF. The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 2000; 26:207-13. [PMID: 10709991 DOI: 10.1016/s8756-3282(99)00278-1] [Citation(s) in RCA: 170] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Osteosclerosis (oc) is an autosomal recessive lethal mutation that impairs bone resorption by osteoclasts, and induces a general increase of bone density in affected mice. Genetic mapping of the oc mutation was used as a backbone in a positional cloning approach in the pericentromeric region of mouse chromosome 19. Perfect cosegregation of the osteopetrotic phenotype with polymorphic markers enabled the construction of a sequence-ready bacterial artificial chromosome (BAC) contig of this region. Genomic sequencing of a 200-kb area revealed the presence of the mouse homologue to the human gene encoding the osteoclast-specific 116-kDa subunit of the vacuolar proton pump. This gene was located recently on human 11q13, a genomic region conserved with proximal mouse chromosome 19. Sequencing of the 5' end of the gene in oc/oc mice showed a 1.6-kb deletion, including the translation start site, which impairs genuine transcription of this subunit. The inactivation of this osteoclast-specific vacuolar proton ATPase subunit could be responsible for the lack of this enzyme in the apical membranes of osteoclast cells in oc/oc mice, thereby preventing the resorption function of these cells, which leads to the osteopetrotic phenotype.
Collapse
Affiliation(s)
- J C Scimeca
- Instabilité et Altérations des Génomes, UMR6549 CNRS/UNSA, Faculté de Médecine de l'Université de Nice-Sophia Antipolis, Nice, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Valentin E, Koduri RS, Scimeca JC, Carle G, Gelb MH, Lazdunski M, Lambeau G. Cloning and recombinant expression of a novel mouse-secreted phospholipase A2. J Biol Chem 1999; 274:19152-60. [PMID: 10383420 DOI: 10.1074/jbc.274.27.19152] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Secreted phospholipases A2 (sPLA2s) form a class of structurally related enzymes that are involved in a variety of physiological and pathological effects including inflammation and associated diseases, cell proliferation, cell adhesion, and cancer, and are now known to bind to specific membrane receptors. Here, we report the cloning and expression of a novel sPLA2 isolated from mouse thymus. Based on its structural features, this sPLA2 is most similar to the previously cloned mouse group IIA sPLA2 (mGIIA sPLA2). As for mGIIA sPLA2, the novel sPLA2 is made up of 125 amino acids with 14 cysteines, is basic (pI = 8.71) and its gene has been mapped to mouse chromosome 4. However, the novel sPLA2 has only 48% identity with mGIIA and displays similar levels of identity with the other mouse group IIC and V sPLA2s, indicating that the novel sPLA2 is not an isoform of mGIIA sPLA2. This novel sPLA2 has thus been called mouse group IID (mGIID) sPLA2. In further contrast with mGIIA, which is found mainly in intestine, transcripts coding for mGIID sPLA2 are found in several tissues including pancreas, spleen, thymus, skin, lung, and ovary, suggesting distinct functions for the two enzymes. Recombinant expression of mGIID sPLA2 in Escherichia coli indicates that the cloned sPLA2 is an active enzyme that has much lower specific activity than mGIIA and displays a distinct specificity for binding to various phospholipid vesicles. Finally, recombinant mGIID sPLA2 did not bind to the mouse M-type sPLA2 receptor, while mGIIA was previously found to bind to this receptor with high affinity.
Collapse
Affiliation(s)
- E Valentin
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, UPR 411, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France
| | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
We have recently discovered a new class of potassium channels with two pore-forming domains and four membrane-spanning domains. When heterologously expressed, these channels produce time- and voltage-independent currents that classify them as background or leak channels. TWIK (for tandem of P domains in a weak inwardly rectifying K+ channel) was the first member of this family to be cloned. Here, we describe the genomic organization of TWIK in the mouse. The coding sequence as well as the untranslated sequences are contained in three exons. The twik gene (or KCNK1) has been mapped to chromosome 8, consistent with its localization to 1q42-43 in human. The twik gene is expressed in virtually all mouse tissues. It is most abundantly expressed in brain and moderately in other organs such as kidney. The level of expression is increased in brain and kidney from neonate to adult animals, but the TWIK message is also detected during embryogenesis, as early as day 7 post conception.
Collapse
Affiliation(s)
- I Arrighi
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UPR 411, Valbonne, France
| | | | | | | | | |
Collapse
|
29
|
Abstract
Mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) is a dual-specificity protein phosphatase encoded by an immediate-early gene responsive to growth factors and stress. The MKP-1 protein selectively inactivates MAP kinases in vitro by dephosphorylation of the regulatory Thr and Tyr residues. Little is known on the mechanisms that regulate MKP-1 gene expression. Here, we demonstrate that Ca2+ is both necessary and sufficient for the induction of MKP-1 gene expression. Treatment of Rat1 fibroblasts with the Ca2+ chelating agent BAPTA completely suppressed serum-induced MKP-1 expression in a dose- and time-dependent manner. The inhibitory effect of BAPTA was observed at the level of the protein and the mRNA. Importantly, Ca2+ chelation blocked the induction of MKP-1 expression in response to all stimuli tested and in different cell types. Increasing the intracellular concentration of Ca2+ with the ionophore A23187 was sufficient to induce MKP-1 mRNA and protein expression in rat fibroblasts. We also provide evidence that activation of MAP kinases is not an absolute requirement for induction of the MKP-1 gene. Exposure of rat fibroblasts to A23187 induced MKP-1 expression without activating the JNK and p38 MAP kinase pathways. Also, inhibition of the ERK pathway with the selective MEK inhibitor PD98059 did not interfere with serum-stimulated MKP-1 mRNA expression. These results will help define the regulatory mechanisms that govern MKP-1 gene transcription in target cells.
Collapse
Affiliation(s)
- J C Scimeca
- Centre de Recherche, Hôtel-Dieu de Montréal and Department of Pharmacology, University of Montreal, Quebec, Canada
| | | | | | | |
Collapse
|
30
|
Peraldi P, Frödin M, Barnier JV, Calleja V, Scimeca JC, Filloux C, Calothy G, Van Obberghen E. Regulation of the MAP kinase cascade in PC12 cells: B-Raf activates MEK-1 (MAP kinase or ERK kinase) and is inhibited by cAMP. FEBS Lett 1995; 357:290-6. [PMID: 7835430 DOI: 10.1016/0014-5793(94)01376-c] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In PC12 cells, cAMP stimulates the MAP kinase pathway by an unknown mechanism. Firstly, we examined the role of calcium ion mobilization and of protein kinase C in cAMP-stimulated MAP kinase activation. We show that cAMP stimulates p44mapk independently of these events. Secondly, we studied the role of B-Raf in this process. We observed that NGF, PMA and cAMP induce the phosphorylation of B-Raf as well as an upward shift in its electrophoretic mobility. We show that B-Raf is activated following NGF and PMA treatment of PC12 cells, and that it can phosphorylate and activate MEK-1. However, cAMP inhibits B-Raf autokinase activity as well as its ability to phosphorylate and activate MEK-1. This inhibition is likely to be due to a direct effect since we found that PKA phosphorylates B-Raf in vitro. Further, we show that B-Raf binds to p21ras, but more important, this binding to p21ras is virtually abolished with B-Raf from PC12 cells treated with CPT-cAMP. Hence, these data indicate that the PKA-mediated phosphorylation of B-Raf hampers its interaction with p21ras, which is responsible for the PKA-mediated decrease in B-Raf activity. Finally, our work suggests that in PC12 cells, cAMP stimulates MAP kinase through the activation of an unidentified MEK kinase and/or the inhibition of a MEK phosphatase.
Collapse
Affiliation(s)
- P Peraldi
- INSERM U 145, Faculté de Médecine, Nice, France
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Peraldi P, Scimeca JC, Filloux C, Van Obberghen E. Regulation of extracellular signal-regulated protein kinase-1 (ERK-1; pp44/mitogen-activated protein kinase) by epidermal growth factor and nerve growth factor in PC12 cells: implication of ERK1 inhibitory activities. Endocrinology 1993; 132:2578-85. [PMID: 8389283 DOI: 10.1210/endo.132.6.8389283] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
In PC12 cells, extracellular signal-regulated kinase-1 (ERK1 or pp44/mitogen-activated protein kinase) is stimulated in response to epidermal growth factor (EGF) and nerve growth factor (NGF). This stimulation is rapid and short-lived after EGF activation. In contrast, NGF promotes a swift, but persistent, ERK1 stimulation. We took advantage of this difference in activation pattern to study the negative regulation of ERK1. Using antibodies to the C-terminus of ERK1, we performed in vitro reconstitution experiments with immunoprecipitated ERK1 from stimulated cells and extracts from PC12 cells incubated with EGF or NGF for various periods of times. Using this approach, we showed that extracts from unstimulated cells reduce ERK1 activity. Upon exposure of cells to NGF or EGF, we found that the inhibitory activity had a pattern opposite that of ERK1 phosphorylation and activity. Indeed, the highest ERK1 activation was associated with the lowest ERK1-repressing activity and vice versa. This ERK1 inhibitory activity was found to be sensitive mainly to sodium orthovanadate and to a lesser extent to zinc acetate. Interestingly, okadaic acid decreased ERK1-repressing activity from unstimulated cells when tested with ERK1 from 5-min NGF-treated cells, but not with ERK1 from 5-min EGF-treated cells. Hence, ERK1 appears to be regulated differently after stimulation of cells with EGF compared to NGF. We show that cell extracts promote ERK1 dephosphorylation. Indeed, we were able to detect a phosphatase activity toward in vivo phosphorylated ERK1 that was regulated differently after NGF and EGF treatments of the cells, and that has a profile of regulation similar to that of the ERK1 inhibitory activity. This regulatable phosphatase activity was also observed using in vitro phosphorylated ERK1. Taken together, our data provide evidence that ERK1 is negatively controlled by a phosphatase(s) that can undergo differential modulation depending on the stimuli used.
Collapse
Affiliation(s)
- P Peraldi
- INSERM U 145, Faculté de Médecine, Nice, France
| | | | | | | |
Collapse
|
32
|
Nguyen TT, Scimeca JC, Filloux C, Peraldi P, Carpentier JL, Van Obberghen E. Co-regulation of the mitogen-activated protein kinase, extracellular signal-regulated kinase 1, and the 90-kDa ribosomal S6 kinase in PC12 cells. Distinct effects of the neurotrophic factor, nerve growth factor, and the mitogenic factor, epidermal growth factor. J Biol Chem 1993; 268:9803-10. [PMID: 8387505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
We recently characterized the association of the 44-kDa mitogen-activated protein kinase, also known as extracellular-regulated kinase 1 (ERK1), with the 90-kDa ribosomal S6 kinase (pp90rsk), one of its putative substrates in intact PC12 cells. Using antibodies to ERK1 that precipitate a functional ERK1.pp90rsk phosphoprotein complex, we demonstrate here the regulation of both kinases by various stimuli. In mouse fibroblasts expressing human insulin receptors, insulin and vanadate swiftly stimulated ERK1 activity within 5 min. While the hormonal effect was short-lived, vanadate led to a first peak followed by a progressively increasing second phase. In PC12 cells, epidermal growth factor, which is a growth promoting factor, provokes a rapid but evanescent activation of ERK1. In contrast, nerve growth factor (NGF), which acts as a neuronal differentiation factor for PC12 cells, induced a swift monophasic response followed by a sustained second phase. This strikingly different pattern of ERK1 stimulation by NGF and epidermal growth factor was associated to a contrasting effect on ERK1 cellular translocation. Thus, NGF induced a nuclear translocation of ERK1, while epidermal growth factor was without noticeable effect on ERK1 localization. In both cell systems all effectors tested stimulated ERK1 phosphorylation on both threonine and tyrosine residues in an 1:1 ratio. During ERK1 inactivation, phosphothreonine and phosphotyrosine were dephosphorylated in a similar fashion. Concurrent with ERK1 activation was the de novo appearance of phosphothreonine and an increase in phosphoserine on pp90rsk. The pp90rsk phosphothreonine content paralleled the ERK1 activity more closely than the phosphoserine level. These results provide compelling evidence that in fibroblasts and PC12 cells ERK1 plays a direct role in the phosphorylation of pp90rsk and that pp90rsk represents a physiologically relevant substrate of extracellular-regulated kinases. Finally, we would like to suggest that the differentiating action of NGF in PC12 cells might be due, at least in part, to the conjunction of its sustained and robust stimulation of ERK1 and pp90rsk, and of its induction of ERK1 nuclear translocation.
Collapse
Affiliation(s)
- T T Nguyen
- Institut National de la Santé et de la Recherche Médicale U145, Faculté de Médecine, Nice, France
| | | | | | | | | | | |
Collapse
|
33
|
Vouret-Craviari V, Van Obberghen-Schilling E, Scimeca JC, Van Obberghen E, Pouysségur J. Differential activation of p44mapk (ERK1) by alpha-thrombin and thrombin-receptor peptide agonist. Biochem J 1993; 289 ( Pt 1):209-14. [PMID: 8380983 PMCID: PMC1132151 DOI: 10.1042/bj2890209] [Citation(s) in RCA: 144] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
alpha-Thrombin (thrombin), a potent mitogen for CCL39 hamster lung fibroblasts, stimulates phosphoinositide-specific phospholipase C (PI-PLC) and inhibits adenylate cyclase via cleavage of a specific G-protein-coupled receptor (TH-R), recently cloned from human and hamster cells. This action can be entirely mimicked by the synthetic peptide SFFLRNP, referred to here as TMP (thrombin-mimicking peptide). TMP corresponds to the first seven amino acids of the new N-terminus generated by thrombin cleavage of the hamster TH-R. Although thrombin and TMP apparently generate identical early transmembrane signals, only thrombin is mitogenic on its own. TMP needs to be associated with fibroblast growth factor (FGF), a tyrosine kinase-activating growth factor, to induce cell-cycle re-entry. Here, we have examined the early and late phase of p44 MAP kinase (p44mapk) activation in G0-arrested CCL39 cells after stimulation by thrombin, TMP, FGF or TMP+FGF. We found that: (i) both thrombin and TMP rapidly activate p44mapk in a dose-dependent manner with maximum activation at around 5 min, (ii) after the initial burst of activation, a second and long-lasting wave of activation is observed in response to thrombin (10-100 nM) but not to TMP (up to 300 microM), (iii) FGF alone (25 ng/ml), like thrombin, rapidly and persistently activates p44mapk (20-fold at 5 min and about 3-fold after 2 h), (iv) TMP added together with FGF strongly potentiates the second and sustained phase of p44mapk activation. From these results we propose that: (1) thrombin-induced mitogenesis is mediated only in part by the TH-R recently cloned and (2) activation of p44mapk, in particular the long-lasting phase that correlates with DNA synthesis, is an obligatory event for cell-cycle re-entry.
Collapse
|
34
|
Scimeca JC, Nguyen TT, Filloux C, Van Obberghen E. Nerve growth factor-induced phosphorylation cascade in PC12 pheochromocytoma cells. Association of S6 kinase II with the microtubule-associated protein kinase, ERK1. J Biol Chem 1992; 267:17369-74. [PMID: 1324933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Microtubule-associated protein (MAP) kinases form a group of serine/threonine kinases stimulated by various growth factors such as nerve growth factor (NGF) and hormones such as insulin. Interestingly, MAP kinases are thought to participate in a protein kinase cascade leading to cell growth as they have been shown to phosphorylate and activate ribosomal protein S6 kinase. To further evaluate the interactions between the different components of this cascade, we looked at the possible coprecipitation of MAP kinase activator(s) or MAP kinase substrate(s) with MAP kinase. Using antipeptides to the C terminus of the M(r) 44,000 MAP kinase, ERK1, and cell extracts from unstimulated or NGF-treated PC12 cells, we obtained in addition to MAP kinase itself coprecipitation of a protein with a M(r) in the 90,000 range. We further show that this protein is a protein kinase since it becomes phosphorylated on serine residues, after sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transfer to a polyvinylidene difluoride membrane. In vitro phosphorylation performed before sodium dodecyl sulfate-polyacrylamide gel electrophoresis demonstrates NGF-sensitive phosphorylation of this 90-kDa protein on both serine and threonine; the serine phosphorylation is likely to be due to autophosphorylation, and the threonine phosphorylation due to phosphorylation by the copurifying MAP kinase. Furthermore, immunoprecipitation of this 90-kDa protein was obtained with antibodies to S6 kinase II. Finally, using in situ chemical cross-linking, we were able to demonstrate in intact cells the occurrence of an anti-ERK1 immunoreactive species with a molecular mass of approximately 125,000 compatible with a complex between ERK1 and a 90-kDa S6 kinase. Taken together, our observations demonstrate that the 44-kDa MAP kinase is associated, in intact PC12 cells, with a protein kinase which is very likely to be S6 kinase II. In conclusion, our data represent strong evidence for a physiological role of the MAP kinase-S6 kinase cascade in PC12 cells. Finally, our antipeptides provide us with a powerful tool to search for additional physiologically relevant substrates for MAP kinase, a key integrator enzyme for growth factors and hormones.
Collapse
Affiliation(s)
- J C Scimeca
- Institut National de la Santé et de la Recherche Médicale U145, Faculté de Médecine, Nice, France
| | | | | | | |
Collapse
|
35
|
Scimeca JC, Ballotti R, Filloux C, Van Obberghen E. Insulin and orthovanadate stimulate multiple phosphotyrosine-containing serine kinases. Mol Cell Biochem 1992; 109:139-47. [PMID: 1378174 DOI: 10.1007/bf00229768] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Using the synthetic peptide substrate Kemptide and cytosolic extracts of mouse fibroblasts transfected with a human insulin receptor cDNA construct, we have studied an insulin-sensitive serine kinase activity. This activity is rapidly stimulated by insulin (maximum within 5 min) and also by orthovanadate. During cell extract preparation, para-nitrophenylphosphate and phosphotyrosine are able to preserve the enzyme activity, while phosphothreonine and phosphoserine fail to do so. Using antiphosphotyrosine antibodies, specific immunoprecipitation of this insulin- and orthovanadate-sensitive serine kinase was obtained. We then analysed by gel filtration chromatography eluates containing tyrosine-phosphorylated proteins obtained from unstimulated, insulin- and vanadate-treated cells. We found that several activities, with molecular weights estimated to be 30 kDa and smaller, are stimulated by both, insulin and orthovanadate. As a whole, our data indicate that insulin and orthovanadate enhance the cytosolic content in at least 2 or 3 phosphotyrosine-containing serine kinase activities.
Collapse
Affiliation(s)
- J C Scimeca
- INSERM U 145, Faculté de Médecine, Nice, France
| | | | | | | |
Collapse
|
36
|
Ballotti R, Tartare S, Chauvel A, Scimeca JC, Alengrin F, Filloux C, Van Obberghen E. Phenylarsine oxide stimulates a cytosolic tyrosine kinase activity and glucose transport in mouse fibroblasts. Exp Cell Res 1991; 197:300-6. [PMID: 1659989 DOI: 10.1016/0014-4827(91)90436-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In the present report we further approach the mechanism by which insulin and phenylarsine oxide (PAO), a trivalent arsenical compound, regulate glucose transport in mouse fibroblasts (NIH3T3). First, we show that PAO is a powerful stimulatory agent on glucose transport. Second, at least three series of observations indicate that this action of PAO is not mediated through the insulin receptor: (i) the same effect of PAO is observed in NIH3T3 and in transfected cells expressing 6 x 10(6) insulin receptors, while the effect of insulin is markedly increased in the transfected cells; (ii) PAO does not affect the tyrosine phosphorylation of the insulin receptor; (iii) the tyrosine kinase activity of the insulin receptor toward exogenous substrates is not increased by PAO. Since PAO appears to act on glucose transport by a different mechanism than insulin, we have compared the effect of PAO and insulin on tyrosine phosphorylation of cellular proteins. Using Western blot analysis we did not detect common substrates in PAO- and insulin-treated cells. However, we found in cell extracts from both PAO- and insulin-treated cells a 50-kDa protein that is immunoprecipitated by antiphosphotyrosine antibody. In addition, PAO activates a cytosolic tyrosine kinase capable of poly(Glu/Tyr) phosphorylation. As a whole, our data suggest that the 50-kDa protein found in cells incubated with PAO and insulin could be the convergence point of the insulin and PAO signaling pathways.
Collapse
Affiliation(s)
- R Ballotti
- INSERM U145, Faculté de Médecine, Nice, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Scimeca JC, Ballotti R, Nguyen TT, Filloux C, Van Obberghen E. Tyrosine and threonine phosphorylation of an immunoaffinity-purified 44-kDa MAP kinase. Biochemistry 1991; 30:9313-9. [PMID: 1716457 DOI: 10.1021/bi00102a025] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We have approached the functioning of a MAP kinase, which is thought to be a "switch kinase" in the phosphorylation cascade initiated from various receptor tyrosine kinases including the insulin receptor. To do so, antipeptide antibodies were raised against the C-terminal portion of ERK1 (extracellular signal-regulated kinase 1), a protein kinase belonging to the family of MAP kinases. With these antipeptide antibodies, we observed the following: (i) a 44-kDa protein can be specifically recognized both under native and denaturing conditions; (ii) a 44-kDa phosphoprotein can be revealed in 32P-labeled cells; its phosphorylation is stimulated by insulin, sodium orthovanadate, and okadaic acid; (iii) a MBP kinase activity can be precipitated, which phosphorylates MBP on threonine residues, and which is stimulated by insulin, sodium orthovanadate, okadaic acid, and fetal calf serum; (iv) this MBP kinase activity appears to be correlated with the in vivo induced phosphorylation of the 44-kDa protein. We next studied the in vitro phosphorylation of this 44-kDa/ERK1-immunoreactive protein. A time- and manganese-dependent phosphorylation was stimulated by the in vitro addition of sodium orthovanadate. Phosphoamino acid analysis of the in vitro phosphorylated 44-kDa protein revealed both threonine and tyrosine phosphorylation. Importantly, this in vitro phosphorylation of MAP kinase results in activation of phosphorylation of added MBP substrate. As a whole, our data indicate that the 44-kDa phosphoprotein identified by our antipeptide antibodies very likely corresponds to a MAP kinase.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J C Scimeca
- INSERM U145, Faculté de Médecine, Nice, France
| | | | | | | | | |
Collapse
|
38
|
Baron V, Gautier N, Komoriya A, Hainaut P, Scimeca JC, Mervic M, Lavielle S, Dolais-Kitabgi J, Van Obberghen E. Insulin binding to its receptor induces a conformational change in the receptor C-terminus. Biochemistry 1990; 29:4634-41. [PMID: 2196938 DOI: 10.1021/bi00471a019] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Antibodies against peptides corresponding to sequences in the C-terminus of the insulin receptor beta-subunit were used to approach the putative role of this receptor domain in signal generation. Two sequences were chosen and correspond to peptide C1, comprising amino acids 1309-1326, and peptide C2, comprising amino acids 1294-1317. The two antibodies produced distinct immunoprecipitation patterns as a function of the insulin receptor form and recognized changes in the insulin receptor molecule induced by ligand binding and autophosphorylation. Both antipeptides, anti-C1 and anti-C2, showed an important decrease in their recognition capacity for the receptor occupied by insulin when compared to the empty receptor. Further, anti-C1 had a lower affinity for the phosphorylated receptor compared to the unphosphorylated receptor and failed to recognize a fraction of the phosphoreceptor population. In contrast, anti-C2 had similar affinities for the phosphorylated and unphosphorylated receptors but was unable to interact with part of the unphosphorylated receptors. Finally, using immunoblotting of the receptor to analyze the denatured molecules, we showed that the phosphorylation-induced changes detected by anti-C1 are retained, suggesting that they are likely not of a conformational nature. In contrast, the insulin-induced changes in the receptor molecule disappear with receptor denaturation which points to their reversible nature. We conclude from these data that (i) antipeptides against the receptor C-terminal sequence are able to distinguish between phosphorylated and unphosphorylated receptor forms and (ii) binding of insulin to its receptor leads to a reversible, phosphorylation-independent, and possibly conformational change at the level of the receptor C-terminal domain.
Collapse
Affiliation(s)
- V Baron
- Institut National de la Santé et de la Recherche Médicale, INSERM U145, Faculté de Médecine, Nice, France
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Ballotti R, Lammers R, Scimeca JC, Dull T, Schlessinger J, Ullrich A, Van Obberghen E. Intermolecular transphosphorylation between insulin receptors and EGF-insulin receptor chimerae. EMBO J 1989; 8:3303-9. [PMID: 2583100 PMCID: PMC401464 DOI: 10.1002/j.1460-2075.1989.tb08491.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
The insulin receptor, a glycoprotein consisting of two extracellular alpha- and two transmembrane beta-subunits, is thought to mediate hormone action by means of its tyrosine-specific protein kinase activity. To explore the mechanism of insulin receptor phosphorylation we have used NIH3T3 cells transfected with two receptor constructs: one encoding a chimeric receptor composed of the extracellular domain of the human EGF receptor and the cytosolic domain of the human insulin receptor beta-subunit, and a second construct encoding a kinase-defiecient human insulin receptor. Stimulation of these cells with EGF induced tyrosine autophosphorylation of the EGF-insulin receptor chimera (150 kd) and tyrosine phosphorylation of the beta-subunit of the kinase-deficient insulin receptor (95 kd). The phosphopeptides of the autophosphorylated cytoplasmic domain of the EGF-insulin receptor chimera were comparable to those of the transphosphorylated beta-subunit of the kinase-deficient insulin receptor and of the wild-type human insulin receptor. When immunoaffinity purified EGF-insulin receptor hybrids and kinase-deficient insulin receptors were used in a cell lysate phosphorylation assay, it was found that addition of EGF produced 32P-labeling of both receptor species. We conclude that EGF acting directly through the EGF-insulin receptor chimera causes transphosphorylation of the kinase-deficient insulin receptor. These data support the notion that autophosphorylation of the insulin receptor may proceed by an intermolecular mechanism.
Collapse
Affiliation(s)
- R Ballotti
- INSERM U 145, Faculté de Médecine, Nice, France
| | | | | | | | | | | | | |
Collapse
|
40
|
Scimeca JC, Ballotti R, Alengrin F, Honegger AM, Ullrich A, Schlessinger J, Obberghen EV. Metabolic effects induced by epidermal growth factor (EGF) in cells expressing EGF receptor mutants. J Biol Chem 1989; 264:6831-5. [PMID: 2785109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The epidermal growth factor (EGF) receptor tyrosine kinase activity is required for both the earliest EGF-stimulated post-binding events (enhancement of inositol phosphate formation and Ca2+ influx, activation of Na+/H+ exchange), and the ultimate EGF-induced mitogenic response. To assess the role of EGF receptor kinase in EGF-induced metabolic effects (2-deoxyglucose and 2-aminoisobutyric acid uptake), we used NIH3T3 cells (clone 2.2), which do not possess endogenous EGF receptors and which were transfected with cDNA constructs encoding either wild type or kinase-deficient human EGF receptor (HER). In addition, we tested the importance of three HER autophosphorylation sites (Tyr-1068, Tyr-1148, and Tyr-1173) in transduction of EGF-stimulated 2-deoxyglucose uptake. Taking our data together, we conclude the following: (i) HER tyrosine kinase activity is required to elicit EGF stimulation of both 2-deoxyglucose and 2-aminoisobutyric acid uptake; (ii) mutations on individual HER autophosphorylation sites, Tyr-1068, Tyr-1148, and Tyr-1173 do not impair EGF-stimulated 2-deoxyglucose uptake.
Collapse
Affiliation(s)
- J C Scimeca
- Institut National de la Santé et de la Recherche Médicale U145, Faculté de Médecine, Nice, France
| | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Insulin elicits the autophosphorylation of the beta-subunit of its receptor on tyrosine residues: this effect appears to be the earliest post-binding event involved in insulin action. In the present study we have raised highly specific antibodies to phosphotyrosine residues, and we have taken advantage of these antibodies to further evaluate the role of the insulin receptor tyrosine kinase in the generation of insulin's biological responses. Using a cell-free phosphorylation assay, we show here that these antibodies increase the tyrosine kinase activity of the receptor, and its phosphorylation on tyrosine residues. In contrast, the antibodies do not interfere with dephosphorylation of the insulin receptor. Introduction of the same antibodies in living Fao hepatoma cells enhances the effect of insulin on both glucose transport and aminoacid uptake. As a whole our data indicate that the insulin receptor kinase is involved in the generation of an early (glucose transport) and late (aminoacid uptake) response to insulin. Further, conformational changes in phosphotyrosine containing domains of the insulin receptor appear to modulate insulin's biological effects. Finally, the injection of antibodies in intact cells provides us with a novel and promising tool to search for cellular substrates for the insulin receptor tyrosine kinase.
Collapse
Affiliation(s)
- R Ballotti
- Institut National de la Santé et de la Recherche Médicale U 145, Faculté de Médecine, Nice, France
| | | | | | | |
Collapse
|